Douglas Laux

4.0k total citations
34 papers, 674 citations indexed

About

Douglas Laux is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Douglas Laux has authored 34 papers receiving a total of 674 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Douglas Laux's work include Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Epigenetics and DNA Methylation (7 papers). Douglas Laux is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Epigenetics and DNA Methylation (7 papers). Douglas Laux collaborates with scholars based in United States, Australia and United Kingdom. Douglas Laux's co-authors include Pearlly S. Yan, Dennis B. Lubahn, Charles W. Caldwell, Tim H.‐M. Huang, Adam L. Asare, Hien Tran, Phong Tran, Mohammed Milhem, Tim H.M. Huang and Bruce A. Smith and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Douglas Laux

30 papers receiving 652 citations

Peers

Douglas Laux
Dariusz Boroń Poland
Patrick Beaulieu Canada
Ricardo N. Ramírez United States
В. Н. Максимов Russia
Diane Check United States
Christine R. Keenan Australia
Mengwen Hu China
Onur Baykara Türkiye
Yoshiko Hirano Japan
Allen Mao United States
Dariusz Boroń Poland
Douglas Laux
Citations per year, relative to Douglas Laux Douglas Laux (= 1×) peers Dariusz Boroń

Countries citing papers authored by Douglas Laux

Since Specialization
Citations

This map shows the geographic impact of Douglas Laux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Laux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Laux more than expected).

Fields of papers citing papers by Douglas Laux

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Laux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Laux. The network helps show where Douglas Laux may publish in the future.

Co-authorship network of co-authors of Douglas Laux

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Laux. A scholar is included among the top collaborators of Douglas Laux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Laux. Douglas Laux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Anbil, Sriram, Nicholas J. Seewald, E. Gabriela Chiorean, et al.. (2025). LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes. JCO Precision Oncology. 9(9). e2500090–e2500090.
3.
Ho, Alan L., Lisle Nabell, Prakash Neupane, et al.. (2024). HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results.. Journal of Clinical Oncology. 42(16_suppl). 6005–6005. 5 indexed citations
4.
Nabell, Lisle M., Alan L. Ho, Marshall R. Posner, et al.. (2023). 921P HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer. Annals of Oncology. 34. S581–S582. 3 indexed citations
5.
Katz, David A., Sarah L. Mott, Kimberly Dukes, et al.. (2021). Time to put it out – nurse-facilitated tobacco treatment in a comprehensive cancer center. Translational Behavioral Medicine. 11(9). 1726–1738. 1 indexed citations
6.
Dillon, Joseph S., David Bushnell, & Douglas Laux. (2021). High-Specific-Activity 131 Iodine-Metaiodobenzylguanidine for Therapy of Unresectable Pheochromocytoma and Paraganglioma. Future Oncology. 17(10). 1131–1141. 1 indexed citations
7.
Laux, Douglas, et al.. (2020). A pathogenic germline BRCA2 variant in a patient with hypopharyngeal squamous cell carcinoma. SHILAP Revista de lepidopterología. 9(1). 429–432. 2 indexed citations
8.
Zandberg, Dan P., Robert L. Ferris, Douglas Laux, et al.. (2020). 71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results. Annals of Oncology. 31. S1446–S1447. 23 indexed citations
9.
Middleton, Mark R., Francesca Aroldi, Joseph J. Sacco, et al.. (2020). An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.. Journal of Clinical Oncology. 38(15_suppl). e22050–e22050. 16 indexed citations
10.
Kolesar, Jill, Heather Green, Douglas Laux, et al.. (2019). A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers. Cancer Prevention Research. 12(12). 903–912. 5 indexed citations
11.
Fertig, Elana J., Laura P. Stabile, Julie E. Bauman, et al.. (2019). A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab. Biomarker Research. 7(1). 14–14. 7 indexed citations
12.
Rodman, Samuel N., Kathleen A. Ross, Isaac J. Jensen, et al.. (2019). Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 7(1). 79–79. 28 indexed citations
13.
14.
15.
Xia, Chang, et al.. (2014). Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Cancer Chemotherapy and Pharmacology. 74(4). 691–697. 55 indexed citations
16.
Xia, Chang, et al.. (2012). A phase I/II study to evaluate the ability of decitabine and panobinostat to improve temozolomide chemosensitivity in metastatic melanoma.. Journal of Clinical Oncology. 30(15_suppl). 3056–3056. 2 indexed citations
17.
Zhang, Liang, Douglas Laux, Keith Munson, et al.. (2004). Dual Therapeutic Utility of Proteasome Modulating Agents for Pharmaco-gene Therapy of the Cystic Fibrosis Airway. Molecular Therapy. 10(6). 990–1002. 40 indexed citations
18.
Yan, Pearlly S., et al.. (2000). Hypermethylation of ribosomal DNA in human breast carcinoma. British Journal of Cancer. 82(3). 514–517. 35 indexed citations
19.
Laux, Douglas, Edward M. Curran, Wade V. Welshons, Dennis B. Lubahn, & Tim H.M. Huang. (1999). Hypermethylation of the Wilms' tumor suppressor gene CpG island in human breast carcinomas. Breast Cancer Research and Treatment. 56(1). 35–43. 38 indexed citations
20.
Laux, Douglas, et al.. (1997). Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique.. PubMed. 57(6). 1030–4. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dariusz Boroń Breakdown of academic impact, for papers by Patrick Beaulieu Breakdown of academic impact, for papers by Ricardo N. Ramírez Breakdown of academic impact, for papers by В. Н. Максимов Breakdown of academic impact, for papers by Diane Check Breakdown of academic impact, for papers by Christine R. Keenan Breakdown of academic impact, for papers by Mengwen Hu Breakdown of academic impact, for papers by Onur Baykara Breakdown of academic impact, for papers by Yoshiko Hirano Breakdown of academic impact, for papers by Allen Mao
Rankless by CCL
2026